Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Antoinet van der Wel"'
Autor:
Merle I. Ronden, MD, Idris Bahce, MD, PhD, Niels J.M. Claessens, MD, Nicole Barlo, MD, Max R. Dahele, MD, PhD, Johannes M.A. Daniels, MD, PhD, Caroline Tissing-Tan, MD, Edo Hekma, MD, Sayed M.S. Hashemi, MD, Antoinet van der Wel, MD, Femke O.B. Spoelstra, MD, PhD, Wilko F.A. R. Verbakel, MD, PhD, Marian A. Tiemessen, MD, Marjolein van Laren, MD, Annemarie Becker, MD, PhD, Svitlana Tarasevych, MD, Cornelis J.A. Haasbeek, MD, PhD, Karen Maassen van den Brink, MD, Chris Dickhoff, MD, PhD, Suresh Senan, MRCP, FRCR, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 7, Pp 100195- (2021)
Introduction: Treatment patterns in stage III NSCLC can vary considerably between countries. The PACIFIC trial reported improvements in progression-free and overall survival with adjuvant durvalumab after concurrent chemoradiotherapy (CCRT). We studi
Externí odkaz:
https://doaj.org/article/3e96940ff5cd4637979bd3b5a74cee6d
Autor:
Edith Dieleman, Lisa van der Woude, Rob van Os, Liselotte van Bockel, Ida Coremans, Corine van Es, Katrien De Jaeger, Hans Peter Knol, Willemijn Kolff, Frederike Koppe, Jacqueline Pomp, Bart Reymen, Dominic Schinagl, Femke Spoelstra, Caroline Tissing-Tan, Noelle van der Voort van Zyp, Antoinet van der Wel, Robin Wijsman, Michel Dielwart, Erwin Wiegman, Ronald Damhuis, Jose Belderbos
Publikováno v:
Clinical Lung Cancer, 24, 2, pp. 130-136
Clinical Lung Cancer, 24, 130-136
Clinical lung cancer, 24(2), 130-136. CIG MEDIA GROUP, LP
Clinical Lung Cancer, 24(2), 130-136. CIG Media Group, L.P.
Clinical lung cancer. Elsevier
Clinical Lung Cancer, 24, 130-136
Clinical lung cancer, 24(2), 130-136. CIG MEDIA GROUP, LP
Clinical Lung Cancer, 24(2), 130-136. CIG Media Group, L.P.
Clinical lung cancer. Elsevier
In this national lung cancer audit of inoperable NSCLC patients, acute toxicity and 3-month mortality of curative chemoradiation was analyzed. Another important question was whether concurrent chemoradiation for elderly stage III NSCLC patients is sa
Autor:
Ludy C.H.W. Lutgens, Monique Hochstenbag, Sebastiaan M. J. J. G. Nijsten, Philippe Lambin, Rinus Wanders, Dirk De Ruysscher, R.J.S. Lamers, Søren M. Bentzen, Brad Wouters, Michael Zimny, Antoinet van Der Wel, Liesbeth J. Boersma
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 61:649-655
Purpose With this modeling study, we wanted to estimate the potential gain from incorporating fluorodeoxyglucose-positron emission tomography (FDG-PET) scanning in the radiotherapy treatment planning of CT Stage N2-N3M0 non–small-cell lung cancer (